KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationAmortizationCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in IntangiblesChange in IntangiblesDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Change in Working Capital (2016 - 2023)

Gsk has reported Change in Working Capital over the past 13 years, most recently at -$3.4 billion for Q3 2023.

  • For Q3 2023, Change in Working Capital fell 330.07% year-over-year to -$3.4 billion; the TTM value through Sep 2023 reached -$3.4 billion, down 330.07%, while the annual FY2022 figure was -$232.2 million, 78.7% up from the prior year.
  • Change in Working Capital for Q3 2023 was -$3.4 billion at Gsk, down from -$232.2 million in the prior quarter.
  • Over five years, Change in Working Capital peaked at -$232.2 million in Q4 2022 and troughed at -$3.4 billion in Q3 2023.
  • A 5-year average of -$1.2 billion and a median of -$1.1 billion in 2019 define the central range for Change in Working Capital.
  • Biggest five-year swings in Change in Working Capital: skyrocketed 78.7% in 2022 and later tumbled 330.07% in 2023.
  • Year by year, Change in Working Capital stood at -$1.3 billion in 2019, then soared by 50.62% to -$628.5 million in 2020, then crashed by 73.51% to -$1.1 billion in 2021, then soared by 78.7% to -$232.2 million in 2022, then tumbled by 1355.73% to -$3.4 billion in 2023.
  • Business Quant data shows Change in Working Capital for GSK at -$3.4 billion in Q3 2023, -$232.2 million in Q4 2022, and -$786.1 million in Q3 2022.